The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease

Vishal Gupta, MD

7 comments

  1. Vishal, pretty dramatic findings! We clearly have some work to do in treating VTE in SCD patients! It’s interesting to see how many different AC strategies were employed. The sample size with some of the oral agents is small but the findings are very intriguing! Well-done!
    Dave

  2. Interesting to see some signal of disparity in efficacy for VTE reduction between the DOACs and Coumadin, in contradistinction to what we see in a-fib info (admittedly on larger scale). Agree though that the bleeding risk seems to be lower (and that the intracranial bleeding is a problem!).

  3. Congratulations Vishal! The data is striking indeed and provides reassurance for DOACs.

  4. Your findings are very interesting! The rates of VTE are quite high and warfarin seemed to have a number of issues.

  5. Nice job – would be interesting to see why physicians chose one agent over another to address indication bias. Intriguing results!

Post Your Comment